Antisense oligonucleotides (ASOs) show promise for treating a host of neurodegenerative disorders, now including tauopathies. In collaboration with the pharmaceutical company Ionis in Carlsbad, California, Timothy Miller and his colleagues at Washington University in St. Louis designed a potent ASO …
Author: Mike Nova
Categories
